Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
出版年份 2013 全文链接
标题
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
作者
关键词
-
出版物
CURRENT MEDICAL RESEARCH AND OPINION
Volume 29, Issue 12, Pages 1617-1626
出版商
Informa Healthcare
发表日期
2013-08-23
DOI
10.1185/03007995.2013.837817
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pharmacologic Management of Type 2 Diabetes
- (2013) William Harper et al. Canadian Journal of Diabetes
- We've Come a Long Way…Haven't We?
- (2013) Michael Vallis Canadian Journal of Diabetes
- Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial
- (2013) B. Charbonnel et al. DIABETOLOGIA
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?
- (2013) Belinda Gier et al. JAMA Internal Medicine
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- A Retrospective Audit of Type 2 Diabetes Patients Prescribed Liraglutide in Real-Life Clinical Practice
- (2013) Ciara M. Mulligan et al. Diabetes Therapy
- Recent advances in incretin-based therapies
- (2012) David Russell-Jones et al. CLINICAL ENDOCRINOLOGY
- Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial
- (2012) R. E. Pratley et al. DIABETES CARE
- -Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy
- (2012) L. B. Harrison et al. DIABETES CARE
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population
- (2012) John A. Romley et al. Diabetes Technology & Therapeutics
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Liraglutide Achieves A1C Targets More Often Than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C
- (2012) Allen King et al. Endocrine Practice
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
- (2012) Marc Evans et al. Diabetes Therapy
- Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study
- (2012) Juyoung Shin et al. Diabetes & Metabolism Journal
- Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes
- (2011) Baptist Gallwitz et al. ACTA DIABETOLOGICA
- Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada
- (2011) Manoela F.B. Braga et al. CANADIAN JOURNAL OF CARDIOLOGY
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
- (2011) Richard M. Bergenstal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
- (2011) Stuart A. Ross et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
- (2011) Steven P Marso et al. Diabetes & Vascular Disease Research
- Achieving a clinically relevant composite outcome of an HbA1c of
- (2011) B. Zinman et al. DIABETES OBESITY & METABOLISM
- Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
- (2011) Giuseppe Derosa et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
- (2011) S. S. Torekov et al. Obesity Reviews
- Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
- (2011) Kohei Kaku et al. Journal of Diabetes Investigation
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
- (2010) Y. Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
- (2010) Deepson S Shyangdan et al. BMC Endocrine Disorders
- Standards of Medical Care in Diabetes--2009
- (2009) DIABETES CARE
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Secondary Failure of Metformin Monotherapy in Clinical Practice
- (2009) J. B. Brown et al. DIABETES CARE
- One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial
- (2009) M. C. Bunck et al. DIABETES CARE
- Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
- (2009) D. I. Brixner et al. DIABETES OBESITY & METABOLISM
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now